The success rate of Gravibinon injections, based on the provided data, is a 66.7% pregnancy rate. Here's a breakdown of the results:
Gravibinon Injection Outcomes
The study identified several outcomes following Gravibinon treatment. Here's a detailed look at each one:
-
Pregnancy Rate: The primary success metric was the achievement of pregnancy.
- 66.7% of patients achieved a confirmed pregnancy. This is the most direct measure of Gravibinon’s effectiveness.
-
Biochemical Pregnancy: In some cases, early hormonal changes indicated a pregnancy, but it did not develop into a clinical pregnancy.
- 9.8% of patients experienced a biochemical pregnancy, as detected through hormone measurements.
- Notably, these biochemical pregnancies were not influenced by Gravibinon treatment, suggesting other factors were involved.
-
Empty Cavity: A small percentage of cases resulted in an empty cavity.
- 3.9% of patients were found to have an empty cavity. This is a finding that warrants further investigation but does not contribute to the success rate.
Key Takeaways
The success of Gravibinon treatment is focused on achieving a viable pregnancy. It’s essential to understand:
- The primary success is the 66.7% pregnancy rate.
- Biochemical pregnancies (9.8%) are not directly linked to Gravibinon’s effectiveness.
- Empty cavity cases (3.9%) do not contribute to the success rate calculation.
Therefore, while other outcomes were observed, the main measure of Gravibinon injection success is the 66.7% pregnancy rate.
